AssetMark Inc’s INmune Bio INMB Stock Holding History

AssetMark Inc’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-150	Closed	-$234	–	3518
2025 Q4	$234	Buy	+150	New	+$268	﹤0.01%	3238

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AssetMark Inc's INMB Position: Q1 2026 in Review

AssetMark Inc sold out of INmune Bio (INMB) in Q1 2026, closing a stake of 150 shares — an estimated $234 sold.

AssetMark Inc first reported a position in INMB in Q4 2025 and held it in 1 quarter. The position peaked at $234 in Q4 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

AssetMark Inc reported no remaining INmune Bio position as of Q1 2026 after selling out during the quarter.
AssetMark Inc sold 150 INmune Bio shares in Q1 2026, an estimated $234.
AssetMark Inc first reported a position in INmune Bio in Q4 2025 and held it in 1 quarter.
AssetMark Inc's INmune Bio position peaked at $234 in Q4 2025.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.